# Evaluation of TQ-B3234 Capsules in Patients With Symptomatic, Non-Surgical Type 1 Neurofibromatosis-Associated Plexiform Neurofibromas

Source: https://onco.cc/trials/nct07407803/  
OnCo record `nct07407803` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing TQ-B3234 in rare cancers of childhood, now recruiting.

## Summary

Evaluation of TQ-B3234 Capsules in Patients With Symptomatic, Non-Surgical Type 1 Neurofibromatosis-Associated Plexiform Neurofibromas is a phase 3 interventional study registered as NCT07407803, led by Chia Tai Tianqing Pharmaceutical, and recruiting on the registry. Official title: Randomised, Double-Blind, Parallel-Controlled, Multicenter Phase III Clinical Trial Evaluating the Efficacy and Safety of TQ-B3234 Capsules Versus Placebo in Patients With Symptomatic, Non-Surgical Type 1 Neurofibromatosis-Associated Plexiform Neurofibromas. Planned enrolment is 177 participants (estimated). The study started in 2026-03-31 and primary completion is expected in 2027-12. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-11
- Tags: ctgov-ingest
- Registry id: NCT07407803
- Phase: 3
- Setting: Randomized, Double-Blind, Parallel-Controlled, Multicenter Phase III Clinical Trial Evaluating the Efficacy and Safety of TQ-B3234 Capsules Versus Placebo in Patients With Symptomatic, Non-Surgical Type 1 Neurofibromatosis-Associated Plexiform Neurofibromas
- Sponsor: Chia Tai Tianqing Pharmaceutical
- Enrolled: 177

## Sources

- ClinicalTrials.gov NCT07407803: https://clinicaltrials.gov/study/NCT07407803

## Connected records

- cancers: [Rare cancers of childhood (NCI PDQ umbrella)](https://onco.cc/cancers/rare-childhood-cancers/)
- drugs: [TQ-B3234](https://onco.cc/drugs/tq-b3234/)
- companies: [Sino Biopharmaceutical (Chia Tai Tianqing)](https://onco.cc/companies/sino-biopharm/)

---
JSON: https://onco.cc/api/v1/entities/nct07407803.json